NCT01196260

Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and III

Clinical Trial on Combination Chemotherapy Treatments in Patients With Colorectal Cancer Stage II and III Among Chinese Population

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 8,000 (estimated)
• Sponsor: State Key Laboratory of Cancer Biology · Network
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

This study will examine a new combination of drugs: Capecitabine and Oxaliplatin for the treatment of Stage II and III colorectal cancer. Capecitabine and Oxaliplatin are approved by the Food and Drug Administration (FDA) for use in colorectal cancer. The combination of drugs is experimental (not approved by the FDA as standard treatment), but is a widely used treatment option and preliminary studies have shown that treatment with the combination has a positive effect on metastatic colorectal cancer.

Detailed description

This study will examine a new combination of drugs: Capecitabine and Oxaliplatinfor for the treatment of Stage II and III colorectal cancer. Capecitabine and Oxaliplatin are approved by the Food and Drug Administration (FDA) for use in colorectal cancer. The combination of drugs is experimental (not approved by the FDA as standard treatment), but is a widely used treatment option and preliminary studies have shown that treatment with the combination has a positive effect on metastatic colorectal cancer. In the present trial, we will study the combination of these two drugs in patients with colorectal cancer among Chinese population

Conditions

• Colorectal Cancer

Interventions

Type	Name	Description
DRUG	Capecitabine and Oxaliplatin	Capecitabine and Oxaliplatin will be under the NSCLC guideline

Timeline

• Start date: 2004-01-01
• Primary completion: 2020-12-01
• Completion: 2020-12-01
• First posted: 2010-09-08
• Last updated: 2018-02-20

Locations

1 site across 1 country: China